Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
-
Gene therapy patients monitored for years to ensure lasting safety
Disease control OngoingThis study follows 8 people with severe sickle cell disease or transfusion-dependent beta-thalassemia who already received a gene therapy called BIVV003 or ST-400. Researchers will check for side effects, survival, and how well the treatment controls their disease over many years…
Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
15-Year Check-In: did the 'Smart' immune cells protect transplanted kidneys?
Knowledge-focused OngoingThis study follows 11 kidney transplant patients who previously received a personalized cell therapy (TX200-TR101) designed to prevent organ rejection. Researchers will monitor their health and kidney function for up to 15 years to see if the therapy remains safe and helps protec…
Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused
Last updated May 04, 2026 16:20 UTC